

1 **Effectiveness of drugs for COVID-19 inpatients in Japanese medical claim data as**

2 **average treatment effects with inverse probability weighted regression adjustment:**

3 **Retrospective observational study**

4

5 Authors

6 Shingo Mitsushima¹ *, Hiromasa Horiguchi² , Kiyosu Taniguchi^{3,4} 

7

8 Affiliations

9 1. National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan

10 2. National Hospital Organization, Meguro-ku, Tokyo, Japan

11 3. National Hospital Organization Mie National Hospital, Tsu, Mie, Japan

12 4. Research Director, The Tokyo Foundation for Policy Research, Minato-ku, Tokyo,


13 Japan

14 5.

15 * Corresponding author

16 E-mail: mitsushi@niid.go.jp (SM)

17

18  These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 **Abstract**

20 Background: Prior studies have indicated that drugs against coronavirus disease 2019
21 (COVID-19) such as antiviral drugs, anti-inflammatory drugs, steroid and antibody
22 cocktails are expected to prevent severe COVID-19 outcomes and death.

23 Object: We analyzed medical claim data in Japan to assess the effectiveness of drugs
24 against COVID-19.

25 Method: We applied an average treatment effect model with inverse probability
26 weighted regression adjustment, to the Medical Information Analysis Databank
27 managed by National Hospital Organization in Japan. The outcome was death during
28 hospitalization. Subjects were all inpatients, inpatients with oxygen therapy, and
29 inpatients with respiratory ventilators, by three age classes: all ages, 65 years old or
30 older, and younger than 65 years old. Data on physical characteristics, underlying
31 diseases, administered drugs, the proportion of mutated strains, and vaccine coverage
32 were used as explanatory variables for logistic regression.

33 Result: Estimated results indicated that only an antibody cocktails (sotrovimab,
34 casirivimab and imdevimab) raised the probability of saving life, even though these
35 drugs were administered in few cases. On the other hand, other drugs might raise the
36 probability of death.

37 Discussion: Results indicated that only antibody cocktails was effective to save life
38 using an average treatment effect model with inverse probability weighted regression
39 adjustment. No other drugs such as remdesivir, dexamethasone, baricitinib and
40 tocilizumab were found to be effective to save life, even in the pseudo-situation of
41 random assignment.

42

43 **Introduction**

44 Coronavirus disease 2019 (COVID-19) is an infectious disease that results
45 from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case of
46 COVID-19 was detected in December 2019 in Wuhan, China. It subsequently spread
47 worldwide. The drug kinds, which included antiviral drugs, antibody cocktails, and
48 steroid and anti-inflammatory drugs, were developed, leading to decreased incidence of
49 severe COVID-19 and death in Japan [1].

50 Earlier studies and clinical trials have investigated the effectiveness of drugs
51 used against COVID-19 such as an antiviral drug (remdesivir) [2], antibody cocktails
52 (casirivimab/imdevimab, sotrovimab and tixagevimab/cilgavimab) [3-7], a steroid
53 (dexamethasone) [8], RNA-dependent RNA polymerase inhibitors (molnupiravir and
54 favipiravir) [9-12], protease inhibitors (nirmatrelvir/ritonavir) [9, 13], a JAK inhibitor
55 (ruxolitinib) [14], and anti-inflammatory drugs (baricitinib and tocilizumab) [15-17]. All
56 are expected to prevent severe COVID-19 outcomes and death. For this study, we
57 considered the real-world effectiveness of drugs against COVID-19.

58 Medical Information Analysis Databank (MIA) is operated by the National
59 Hospital Organization (NHO) in Japan, which provides a database of medical claims
60 from 60 representative NHO hospitals [18]. NHO is one of the biggest hospital

61 organization in Japan, it has about 3.4% of all beds in Japan [19]. We used MIA data to
62 analyze drug effectiveness.

63 In reality, the decision to administer drugs depends on the patient's condition:
64 that is not a random assignment. Generally speaking, patients who are more likely to
65 develop severe illness have higher probability of being administered drugs, which
66 implies a negative association between drugs and death because of selection bias in the
67 observational data. Therefore, non-random choice of drug administration is regarded as
68 an estimate of drug effectiveness.

69 The average treatment effect model with inverse probability weighted
70 regression adjustment might resolve this difficulty statistically but not experimentally
71 [20]. This procedure predicts the likelihood of administration for the drug. Then
72 outcomes were estimated, using logistic regression including dummy variables, whether
73 a drug was administered or not, weighted with the inverse probability of each subject
74 actually belonging to the group estimated by first-step logistic regression for drug
75 administration. It focused more on subjects whose probability of belonging to the group
76 were lower, in other words, less likelihood was regarded as a more nearly random
77 assignment.

78 Researchers in natural science including medicine can conduct the experiments

79 and thus delete selection bias in the choice of subjects, even though experiments are
80 expensive and require a longer period, usually. Conversely, researchers in social
81 sciences cannot conduct experiments to individual's choice. Instead of that, they
82 sometimes use the average treatment effect model with propensity score matching,
83 mainly, for the evaluation of programs to control participants choose to join the
84 program.

85 However, even in medicine, random assignment experiments after launch are
86 difficult. Therefore, situations change after a trial: mutated strains emerge, and vaccine
87 coverage and/or developed treatments might affect drug effectiveness, rendering
88 evaluation impossible. Particularly, mortality is often not used as an outcome for
89 evaluation, even though it is the most important endpoint. Therefore, experiments in
90 medicine for changing situations and mortality might be difficult. To resolve this
91 difficulty, the average treatment effect model was used for evaluation in a changing
92 situation through a statistically pseudo-random assignment experiment. Particularly, it
93 was applied for orthopedic surgery and cardiovascular research [21, 22]. However, these
94 studies used propensity scoring matching method: a simple comparison of outcomes
95 among the treatment group and non-treatment group with almost identical probability to
96 receive treatment. In other words, this method did not control for outcomes other than

97 treatment. It might bias the result by the potential confounder. Therefore, we used
98 another average treatment model with inverse probability weighted regression
99 adjustment. Its second step was weighted regression for the outcome weighted with
100 inverse probability of the first step for whether the patient was treated, or not [23,24]. It
101 can control covariates for outcomes other than whether the patient was treated, or not.
102 Conversely, average treatment effect model with propensity score matching cannot
103 control other condition than whether the patient was treated, or not.

104

105 **Materials and Methods**

106 **Data sources**

107 This study used MIA for confirmed inpatients including their age, sex,
108 underlying diseases, hospitalization week, administered drugs against COVID-19,
109 outcome and oxygen therapy and/or use of respiratory ventilator. We had accessed to
110 these data which could identify individual participants.

111 We used data for vaccine administration published by the Cabinet Secretariat
112 [25]. Moreover, prevalence in mutated strains was referred from a monitoring meeting
113 in Tokyo because MIA included no information about a patient's vaccine status or
114 sublineage in SARS-CoV-2 [26].

115 The study period was January 2020 through March 2022, using data recorded
116 as of May 2022, which was the date we conducted this study. The study area was the
117 entirety of Japan.

118

119 **Subjects**

120 Subjects were all inpatients who were diagnosed as COVID-19 (U07 in ICD10) from
121 January 2020 through March, 2022. We collected the data on all COVID-19 inpatients
122 in MIA data. Some inpatients who were still hospitalized at the end of study period
123 were excluded. The number of inpatients who were diagnosed as COVID-19 in MIA
124 data moves like 6 waves. These waves were classified from the trough of the prior wave
125 to the trough of the current wave using national data [27]. We defined the 1st wave
126 extended from week 1 of 2020 through week 23 of 2020; the 2nd wave lasted from
127 week 24 of 2020 through week 39 of 2020; the 3rd wave was recorded from week 40 of
128 2020 through week 8 of 2021; the 4th wave occurred from week 9 of 2021 through
129 week 24 of 2021; the 5th wave was from week 25 of 2021 through week 47 of 2021;
130 and the 6th wave was from week 48 of 2021 through the end of this study.

131 However, apart from purely medical criteria, the criteria for hospitalization of
132 asymptomatic patients or mild patients who do not require oxygen therapy may be

133 strongly influenced by social conditions, such as lack of medical resources or support
134 for staying and recovering at home. Therefore, we considered not only the inclusion of
135 all subjects but also the limitation of subjects on oxygen therapy or respiratory
136 ventilation.

137 Note that we did not distinguish some patients with initiation drug before
138 oxygen therapy or respiratory ventilation and patients with initiation drug after oxygen
139 therapy or respiratory ventilation. Because timing of drug initiation, and oxygen therapy
140 or respiratory ventilation using were not available in this study. In other words, patient
141 condition when initiation drug was not accounted for drug effectiveness.

142

143 **Definitions of Variables**

144 Physical characteristics: Age and sex.

145 Underlying diseases: We examined cancer (C00-C90 in ICD10), asthma (J45), chronic
146 obstructive pulmonary disease (COPD) (J44), hypertension (I10), heart failure (I50),
147 and DM (E10).

148 Pharmaceutical therapy: We examined the effects of an antiviral drug (remdesivir), an
149 antibody cocktails (sotrovimab and casirivimab/imdevimab), a steroid (dexamethasone),
150 and anti-inflammatory drugs (baricitinib and tocilizumab). The antibody cocktails were

151 not divided by drug such as sotrovimab and casirivimab/imdevimab because the number
152 of antibody cocktails was not sufficient. The overall effects of the antibody cocktails
153 were examined. We also collected the number of prescriptions such as RNA-dependent
154 RNA polymerase inhibitors (molnupiravir and favipiravir), protease inhibitors
155 (nirmatrelvir/ritonavir). Remdesivir, antibody cocktails (sotrovimab and
156 casirivimab/imdevimab), dexamethasone, baricitinib, and tocilizumab were the top five
157 drugs which earlier studies had shown as effective.

158 Vaccine coverage: The complete rate of second dose of vaccine received two weeks prior
159 by age class, as younger than 65 years old (young patients) or 65 years old or older
160 (elderly patients).

161 Mutated strains: Mutated strains were measured by percentage at one week before
162 admission. Omicron included BA.2 or a later sublineage. Alternatively, we used a
163 dummy variable during the 4th–6th wave instead of the proportion of the mutated
164 strains as an explanatory variable, to check robustness. By this specification, the Alpha
165 variant strain emerged and then dominated in the 4th wave. Similarly, the Delta variant
166 strain emerged and then became dominant in the 5th wave, BA.1 strain emerged and
167 then dominated from the 6th wave.

168 Outcome: Death during hospitalization.

169

170 **Statistical analysis**

171 We conducted estimates separately by drug type: remdesivir, antibody cocktails
172 (sotrovimab, casirivimab and imdevimab), dexamethasone, baricitinib, and tocilizumab.

173 The estimation procedure was the average treatment effect model with inverse
174 probability weighted regression adjustment. It consists of two steps. The first step to
175 assess whether the patient was administered a type of drug or not was performed
176 through logistic regression on their physical condition, underlying diseases, drugs,
177 vaccine coverage, and prevalence in mutated strains as explanatory variables. The
178 second step was logistic regression for fatality weighted with inverse probability
179 estimated by the first step. Explanatory variables in this step were binomial variables:
180 whether the patients were administered the considered drug or not.

181 We adopted 5% level as significance level. All statistical analyses were
182 conducted using software (STATA SE 17.0; Stata Corp.).

183

184 **Ethical considerations**

185 This study was approved by the Ethics Committee of Mie Hospital (Approval No.
186 2020-89). Permission to use MIA data was obtained using the NHO (Registration No.

187 1201003).

188

189 **Results**

190 The number of COVID-19 inpatients in this study was 21727. Fig 1 shows the
191 number of COVID-19 inpatients, COVID-19 inpatients with oxygen therapy,
192 COVID-19 inpatients with respiratory ventilation and fatalities due to COVID-19 by the
193 hospitalized week in MIA data. Fig 2 presents the drugs against COVID-19 by the week
194 in which the COVID-19 inpatient administered the drug was admitted to the hospital in
195 MIA data. Fig 1 shows similar trends in COVID-19 inpatients, COVID-19 inpatients
196 with oxygen therapy, COVID-19 inpatients with respiratory ventilation and fatalities
197 due to COVID-19. Fig 2 also shows that all drugs for treating COVID-19 have a similar
198 trend. The most prescribed drugs were dexamethasone, followed by remdesivir,
199 baricitinib, tocilizumab and antibody cocktails (sotrovimab, casirivimab/imdevimab).

200

201 **Fig 1. COVID-19 inpatients, COVID-19 inpatients with oxygen therapy,**
202 **COVID-19 inpatients using respiratory ventilation and fatalities attributed to**
203 **COVID-19 by the hospitalized week in MIA data**

204 Notes: Blue line and orange line show the numbers of COVID-19 inpatients and

205 inpatients with oxygen therapy respectively in MIA data (right scale). Gray line and
206 yellow line show the numbers of COVID-19 inpatients with respiratory ventilator and
207 fatalities due to COVID-19 respectively in MIA data (left scale).

208

209 **Fig 2. Drugs for treating COVID-19 in MIA data**

210 Notes: Blue line and orange line show the numbers of remdesivir and dexamethasone
211 respectively in MIA data (left scale). Gray line, yellow line and light blue line show the
212 numbers of tocilizumab, baricitinib and antibody cocktails (sotrovimab,
213 casirivimab/imdevimab) respectively in MIA data (right scale).

214

215

216 Table 1 shows the characteristics 21727 inpatients. The mean of their age was
217 54.3. The proportion of sex of male and female was almost same. The most common
218 underlying disease was diabetes mellitus followed by hypertension, cancer, heart failure,
219 asthma, and COPD. Dexamethasone was the most prescribed drug, followed by
220 remdesivir, baricitinib, tocilizumab, and antibody cocktails. Fig 3 presents proportions
221 of mutated strains (Alpha, Delta and Omicron variants) in Tokyo and vaccination
222 coverage with two and three doses in Japan. The predominant variant changed from

223 Alpha to Delta in July 2021 and from Delta to Omicron in December 2021. Vaccination
224 coverage with two doses has increased since May 2021 and reached 80% by the end of
225 2021.

226

227 **Table 1. Characteristics of subjects**

Characteristics	All inpatients	
	n	%
Age		
Mean (SD)	54.3 (25.6)	
Sex		
Female	10083	46.4
Underlying diseases		
Cancer	1036	4.8
Hypertension	2820	13
Diabetes mellitus	3241	14.9
Heart failure	825	3.8
Asthma	575	2.6
COPD	217	1.0
Drugs against COVID-19		
Remdesivir	1910	8.8
Dexamethasone	6041	27.8
Tocilizumab	562	2.6
Baricitinib	1087	5.0
Antibody cocktails	525	2.4

228 Note: Range of age was 0-108.

229 Abbreviation: SD: standard deviation, COPD: chronic obstructive pulmonary disease

230

231 **Fig3. Proportions of Alpha, Delta and Omicron variants in Tokyo, in addition to**

232 **vaccination coverage with two and three doses in Japan**

233 Notes: Blue, orange, and gray lines respectively represent the proportions of the Alpha,

234 Delta and Omicron variants. Data of the proportions of the Alpha and Delta variants

235 were published by the Cabinet Secretariat. Yellow and light blue lines respectively

236 represent vaccination coverage with two and three doses in the entire Japanese

237 population. Data of the vaccination coverage were published by the monitoring meeting

238 in Tokyo.

239

240 Table 2 presents the estimation results. Overall, four drugs except for antibody

241 cocktails (sotrovimab, casirivimab/imdevimab), remdesivir, dexamethasone, baricitinib,

242 and tocilizumab had positive treatment effects among those found to be significant. That

243 finding might indicate that these drugs reduce the probability of saving life. Conversely,

244 antibody cocktails had negative treatment effects which indicated a contribution to

245 saving life. Only four pairs were identified to estimate parameters; other combinations

246 were not.

247

248 **Table 2. Estimation Results of Average Treatment using Inverse Probability**
249 **Weighted Regression Adjustment**

Age class	All	65 years old or older	Younger than 65 years old
-----------	-----	-----------------------	---------------------------

	difference	<i>p</i> value	difference	<i>p</i> value	difference	<i>p</i> value
Remdesivir						
Proportion						
All	0.042	0.000	0.099	0.000	0.007	0.331
Oxygen therapy	0.043	0.000	0.070	0.000	0.002	0.746
Respiratory ventilator	0.034	0.370	0.071	0.160	0.001	0.987
Period						
All	0.040	0.000	0.094	0.000	0.006	0.335
Oxygen therapy	0.041	0.000	0.067	0.000	0.002	0.765
Respiratory ventilator	0.031	0.419	0.063	0.194	-0.029	0.415
Dexamethasone						
Proportion						
All	0.039	0.000	0.090	0.000	0.004	0.017
Oxygen therapy	0.032	0.000	0.056	0.000	0.002	0.684
Respiratory ventilator	-0.006	0.833	-0.017	0.670	0.005	0.889
Period						
All	0.039	0.000	0.088	0.000	0.004	0.022
Oxygen therapy	0.031	0.000	0.053	0.000	0.002	0.661
Respiratory ventilator	-0.005	0.858	-0.013	0.735	0.005	0.891
Tocilizumab						
Proportion						
All	0.114	0.000	0.255	0.000	0.025	0.010
Oxygen therapy	0.127	0.000	0.219	0.000	N/A	N/A
Respiratory ventilator	0.098	0.027	N/A	N/A	-0.011	0.776
Period						
All	0.117	0.000	0.259	0.000	0.025	0.010
Oxygen therapy	0.129	0.000	0.219	0.000	N/A	N/A
Respiratory ventilator	0.105	0.016	N/A	N/A	-0.030	0.441
Baricitinib						
Proportion						
All	0.072	0.002	0.371	0.000	-0.001	0.766
Oxygen therapy	0.107	0.006	0.316	0.000	-0.004	0.519
Respiratory ventilator	0.281	0.000	0.376	0.000	N/A	N/A
Period						
All	N/A	N/A	N/A	N/A	N/A	N/A
Oxygen therapy	N/A	N/A	N/A	N/A	N/A	N/A

Respiratory ventilator	N/A	N/A	N/A	N/A	N/A	N/A
<hr/>						
Sotrovimab or casirivimab/imdevimab						
Proportion						
All	-0.042	0.000	-0.097	0.000	-0.001	0.878
Oxygen therapy	-0.074	0.000	-0.125	0.000	N/A	N/A
Respiratory ventilator	N/A	N/A	N/A	N/A	N/A	N/A
Period						
All	N/A	N/A	N/A	N/A	N/A	N/A
Oxygen therapy	N/A	N/A	N/A	N/A	N/A	N/A
Respiratory ventilator	N/A	N/A	N/A	N/A	N/A	N/A

250 **Notes:** Yellow denotes significance. “N/A” denotes not available.

251

252 Overall, all age and older patients had more significant estimators than younger
 253 patients had. Moreover, few significant estimates were found when the subjects were
 254 limited to patients who had used a respiratory ventilator. Only for tocilizumab in all
 255 ages were these found to be significantly positive. Only four parameters were identified
 256 for estimation for antibody cocktails, even though these were all negative and
 257 significant.

258 Estimation results for mutated strains were defined as the proportion, which
 259 was similar with that defined as the period, except for antibody cocktails. Among the
 260 results obtained for antibody cocktails, there is no pair to estimate parameters.

261

262 **Discussion**

263 Results showed that antibody cocktails might contribute to saving life
264 consistently. Our earlier studies, simple logistic regression and estimation using
265 propensity score matching, yielded similar results [28,29]. However, estimation results
266 of propensity score matching method for tocilizumab and baricitinib were, respectively,
267 positive and negative. In this study, we obtained consistent estimated results for
268 tocilizumab and baricitinib. These results indicated that tocilizumab and baricitinib
269 might not contribute to saving life. Even for antibody cocktails, the effects for younger
270 or more severe patients who used respiratory ventilators were not confirmed. Prior study
271 showed that casirivimab/imdevimab, one of antibody cocktails, reduced viral load [3].
272 Antibody cocktails were usually administered for mild COVID-19 patients, that is, they
273 were administered before viral load increased significantly. Therefore, they might be
274 more effective to COVID-19 compared to drugs used for severe COVID-19 patients.
275 The small sample for the younger patients or severe patients might be also another
276 reason.

277 These counterintuitive findings, except for those for antibody cocktails, which
278 are inconsistent with results obtained from earlier studies of the effectiveness of
279 remdesivir and dexamethasone [2, 8], might result from worse matching at the first step.

280 In addition, endogeneity or selection bias might not be controlled well in the decisions
281 to use drugs. Drugs to be administered against COVID-19 depend on the severity of
282 illness in patients. For instance, an earlier report described dexamethasone as effective
283 for severe COVID-19, but as ineffective against mild or moderate COVID-19 [8].
284 Actually, more than antibody cocktails, four other drugs were reportedly more effective
285 for severely ill patients [2-4, 8]. To resolve this apparent contradiction, more
286 information indicating severity might be necessary to make more precise the first step
287 estimation. Moreover, we did not use test results such as those for blood pressure, BMI,
288 or oxygen saturation. Such information must be included in the first step. Inclusion of
289 such data remains as a challenge for future research. The results of antibody cocktails
290 included many “not available”, although drug effectiveness was confirmed in matched
291 cases. This result might be attributed to the small number of antibody cocktails used in
292 patients. In Japan, remdesivir, dexamethasone, baricitinib, casirivimab/imdevimab,
293 sotrovimab, and tocilizumab were approved in May 2020, July 2020, April 2021, July
294 2021, September 2021, and January 2022 respectively [30]. More recently approved
295 drugs are likely to be smaller samples. Accumulating data may resolve this shortcoming.
296 We also have to pay attention to apply the results of this study to all COVID-19 patients
297 because the targets of this study were all inpatients.

298

299 **Limitations**

300 First, we estimated drug effectiveness separately. However, the choice of drug
301 was not actually independent. Therefore, intercorrelation among drugs should be
302 incorporated into the estimation model.

303 Second, because MIA is a database of medical claims, data from the most recent
304 weeks may change during next few months. For this study, data were collected and
305 analyzed from January, 2020 through the end of March, 2022, as of May, 2022. If the
306 study period is extended, the data and its estimation may differ over time.

307 Third, the drugs examined in this study were not necessarily administered to
308 the severest patients. For example, antibody cocktails were often administered to mild
309 patients. However, to simplify the analysis, we did not consider the combination of
310 drugs or change from one considered drug to another drug. This choice might introduce
311 some bias in the results. This process or pattern of drug administration may be
312 important in evaluating drug effectiveness.

313 Fourth, due to data availability, it was not possible to take into account the
314 timing of drug initiation, and oxygen therapy or respiratory ventilation to estimate drug
315 effectiveness. If this information were available, it would be possible to distinguish

316 between patients who were administered drugs before oxygen therapy or respiratory
317 ventilation and patients who were administered drugs after oxygen therapy or
318 respiratory ventilation. It might be useful for more careful estimation to drug
319 effectiveness.

320

321 **Conclusion**

322 The obtained results demonstrated that antibody cocktails for all or older patients might
323 contribute to the saving of life. However, more information, including test results, is
324 necessary for better matching and achievement of definitive conclusions.

325

326 **Data availability**

327 The data in this study are available from the National Hospital Organization, but the
328 availability of these data is restricted because of privacy reasons. These data were used
329 under license for this study and are therefore not available to the public. Data are
330 available from the authors with permission of the Ethics Committee and National
331 Hospital Organization.

332

333 **Acknowledgements**

334 We acknowledge Mr. Masaya Nakadera and Mr. Masato Koizumi, who prepared the
335 database, and thank all hospitals for submitting patient data.

336

337 **Funding**

338 This study was supported by the Ministry of Health, Labour, and Welfare [grant number
339 20HA1005].

340

341 **References**

- 342 1. Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, et al.
343 Changes in the characteristics and outcomes of COVID-19 patients from the early
344 pandemic to the delta variant epidemic: a nationwide population-based study. *Emerg*
345 *Microbes Infect.* 2023;12(1):2155250. doi: 10.1080/22221751.2022.2155250. PubMed
346 PMID: 36469641; PubMed Central PMCID: PMC9788709.
- 347 2. Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, et al.
348 Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019
349 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large
350 Multicenter Observational Cohort. *Clin Infect Dis.* 2022;75(1):e450-e8. doi:
351 10.1093/cid/ciab875. PubMed PMID: 34596223; PubMed Central PMCID:

352 PMCPMC9402660.

353 3. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al.

354 REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N

355 Engl J Med. 2021;385(23):e81. Epub 20210929. doi: 10.1056/NEJMoa2108163.

356 PubMed PMID: 34587383; PubMed Central PMCID: PMCPMC8522800.

357 4. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et

358 al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

359 N Engl J Med. 2021;385(21):1941-50. Epub 20211027. doi: 10.1056/NEJMoa2107934.

360 PubMed PMID: 34706189.

361 5. Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al.

362 Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N

363 Engl J Med. 2022;386(23):2188-200. Epub 20220420. doi: 10.1056/NEJMoa2116620.

364 PubMed PMID: 35443106; PubMed Central PMCID: PMCPMC9069994.

365 6. Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S,

366 et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for

367 early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised,

368 double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-96. Epub

369 20220607. doi: 10.1016/s2213-2600(22)00180-1. PubMed PMID: 35688164; PubMed

370 Central PMCID: PMCPMC9173721.

371 7. Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, et al.

372 AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic

373 Coronavirus Disease 2019. *Clin Infect Dis*. 2023;76(7):1247-56. doi:

374 10.1093/cid/ciac899. PubMed PMID: 36411267; PubMed Central PMCID:

375 PMCPMC10069855.

376 8. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al.

377 Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*.

378 2021;384(8):693-704. Epub 20200717. doi: 10.1056/NEJMoa2021436. PubMed PMID:

379 32678530; PubMed Central PMCID: PMCPMC7383595.

380 9. Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM.

381 Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against

382 mortality, hospitalisation, and in-hospital outcomes among community-dwelling,

383 ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in

384 Hong Kong: an observational study. *Lancet*. 2022;400(10359):1213-22. doi:

385 10.1016/s0140-6736(22)01586-0. PubMed PMID: 36216007; PubMed Central PMCID:

386 PMCPMC9539539.

387 10. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez

- 388 A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in
389 Nonhospitalized Patients. *N Engl J Med.* 2022;386(6):509-20. Epub 20211216. doi:
390 10.1056/NEJMoa2116044. PubMed PMID: 34914868; PubMed Central PMCID:
391 PMCPMC8693688.
- 392 11. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA,
393 Egorova AN, et al. AVIFAVIR for Treatment of Patients With Moderate Coronavirus
394 Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized
395 Clinical Trial. *Clin Infect Dis.* 2021;73(3):531-4. doi: 10.1093/cid/ciaa1176. PubMed
396 PMID: 32770240; PubMed Central PMCID: PMCPMC7454388.
- 397 12. Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, et al. Early
398 favipiravir treatment was associated with early defervescence in non-severe COVID-19
399 patients. *J Infect Chemother.* 2021;27(7):1051-7. Epub 20210417. doi:
400 10.1016/j.jiac.2021.04.013. PubMed PMID: 33902990; PubMed Central PMCID:
401 PMCPMC8052467.
- 402 13. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et
403 al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J*
404 *Med.* 2022;386(15):1397-408. Epub 20220216. doi: 10.1056/NEJMoa2118542.
405 PubMed PMID: 35172054; PubMed Central PMCID: PMCPMC8908851.

- 406 14. Capochiani E, Frediani B, Iervasi G, Paolicchi A, Sani S, Roncucci P, et al.
407 Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19
408 Disease. Analysis of Data Collection From RESPIRE Protocol. *Front Med (Lausanne)*.
409 2020;7:466. Epub 20200804. doi: 10.3389/fmed.2020.00466. PubMed PMID:
410 32850921; PubMed Central PMCID: PMC7417512.
- 411 15. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al.
412 Efficacy and safety of baricitinib for the treatment of hospitalised adults with
413 COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group,
414 placebo-controlled phase 3 trial. *Lancet Respir Med*. 2021;9(12):1407-18. Epub
415 20210901. doi: 10.1016/s2213-2600(21)00331-3. PubMed PMID: 34480861; PubMed
416 Central PMCID: PMC8409066.
- 417 16. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab
418 in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med*. 2021;384(1):20-30.
419 Epub 20201217. doi: 10.1056/NEJMoa2030340. PubMed PMID: 33332779; PubMed
420 Central PMCID: PMC7781101.
- 421 17. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et
422 al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J*
423 *Med*. 2021;384(16):1491-502. Epub 20210225. doi: 10.1056/NEJMoa2100433.

- 424 PubMed PMID: 33631065; PubMed Central PMCID: PMCPMC7953461.
- 425 18. Kanazawa N, Tani T, Imai S, Horiguchi H, Fushimi K, Inoue N. Existing Data
426 Sources for Clinical Epidemiology: Database of the National Hospital Organization in
427 Japan. *Clin Epidemiol.* 2022;14:689-98. Epub 20220519. doi: 10.2147/clep.S359072.
428 PubMed PMID: 35615723; PubMed Central PMCID: PMCPMC9126156.
- 429 19. Ministry of Health, Labour and Welfare. Survey of Medical Institutions.
430 <https://www.mhlw.go.jp/toukei/saikin/hw/iryosd/20a/>. (in Japanese) [accessed on June
431 20, 2022].
- 432 20. Heckman JJ, Ichimura H, Todd PE. Matching As An Econometric Evaluation
433 Estimator: Evidence from Evaluating a Job Training Programme. *The Review of*
434 *Economic Studies.* 1997;64(4):605-54. doi: 10.2307/2971733.
- 435 21. Kane LT, Fang T, Galetta MS, Goyal DKC, Nicholson KJ, Kepler CK, et al.
436 Propensity Score Matching: A Statistical Method. *Clin Spine Surg.* 2020;33(3):120-2.
437 doi: 10.1097/bsd.0000000000000932. PubMed PMID: 31913173.
- 438 22. Deb S, Austin PC, Tu JV, Ko DT, Mazer CD, Kiss A, et al. A Review of
439 Propensity-Score Methods and Their Use in Cardiovascular Research. *Can J Cardiol.*
440 2016;32(2):259-65. Epub 20150523. doi: 10.1016/j.cjca.2015.05.015. PubMed PMID:
441 26315351.

- 442 23. Cattaneo, MD. Efficient semiparametric estimation of multi-valued treatment
443 effects under negligibility. *Journal of Econometrics* 2010;155; 138-154.
- 444 24. Austin PC, Stuart EA. Moving towards best practice when using inverse
445 probability of treatment weighting (IPTW) using the propensity score to estimate causal
446 treatment effects in observational studies. *Stat Med.* 2015;34(28):3661-79. Epub
447 20150803. doi: 10.1002/sim.6607. PubMed PMID: 26238958; PubMed Central
448 PMCID: PMC4626409.
- 449 25. The Cabinet Secretariat. Vaccination against SARS-CoV-2 (in Japanese),
450 <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html> [Accessed February 10,
451 2023].
- 452 26. A monitoring meeting in Tokyo. Conference material,
453 <https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html> [Accessed
454 February 10, 2023].
- 455 27. Ministry of Health, Labour and Welfare. Published database on the number of
456 patients diagnosed as COVID-19 2023,
457 <https://www.mhlw.go.jp/stf/covid-19/open-data.html> [Accessed February 10, 2023].
- 458 28. Mitsushima S, Horiguchi H, Taniguchi K. Risk of Underlying Diseases and
459 Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in

- 460 Japan: Retrospective Observational Study. *Int J Gen Med*. 2023;16:657-72. Epub
461 20230221. doi: 10.2147/ijgm.S394413. PubMed PMID: 36851998; PubMed Central
462 PMCID: PMCPMC9960711.
- 463 29. Mitsushima S, Horiguchi H, Taniguchi K. Drug effectiveness for COVID-19
464 inpatients inferred from Japanese medical claim data using propensity score matching
465 [version 1; peer review: awaiting peer review]. *F1000Research*. 2023;12(398). doi:
466 10.12688/f1000research.131102.1.
- 467 30. Ministry of Health, Labour and Welfare. Clinical Management of Patients with
468 COVID-19 ver. 8.1. <https://www.mhlw.go.jp/content/000936655.pdf> (in Japanese)
469 [accessed on November 8, 2022].




Figure3




Figure1




Figure2